Tonix Pharmaceuticals (TNXP) Q4 2024 Annual Earnings
TNXP·Reported March 18, 2025·Before market open
Tonix Pharmaceuticals reported Q4 2024 revenue of $2.6M, missed analyst consensus of $3.2M by $618.0K. Diluted EPS came in at $-9.77, missed the $-6.23 consensus by $3.54.
Revenue
$2.6Mmissed by $618.0K
Consensus: $3.2MDiluted EPS
$-9.77missed by $3.54
Consensus: $-6.23
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Tonix Pharmaceuticals's Q4 2024 earnings report.
Tonix Pharmaceuticals (TNXP) reported Q4 2024 earnings on March 18, 2025 before market open.
Tonix Pharmaceuticals reported revenue of $2.6M and diluted EPS of $-9.77 for Q4 2024.
Revenue missed the consensus estimate of $3.2M by $618.0K. EPS missed the consensus estimate of $-6.23 by $3.54.
You can read the 10-K periodic report (0001999371-25-002786) directly on SEC EDGAR. The filing index links above go to sec.gov.